Several trials evaluated the pharmacokinetics and clinical activities of culmerciclib in HR+, HER2- breast cancer (NCT03850873; NCT04796623; Chia Tai Tianqing data on file). This evidence concerns the gene ERBB2 and breast carcinoma.